Oramed Reports Fiscal Third Quarter 2025 Financial Results

Accessibility StatementSkip Navigation Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million Management Commentary Nadav Kidron, Chief Executive Officer of Oramed, commented: "Our disciplined investment strategy is delivering strong results. The complete $100 million cash repayment from Scilex, combined with substantial unrealized gains from our Alpha Tau position an other investments, has driven our $65 million net income and positioned us with ...